Technology Appraisal Committee Meeting (Committee C)

Minutes: Confirmed

Date and Time: Tuesday 23 January 2018, 10:00 to 16:00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Chair Prof Stephen O’Brien Present for all notes
2. Prof Andrew Renehan Present for all notes
3. Mr David Chandler Present for all notes
4. Dr Derek Ward Present for all notes
5. Ms Gail Coster Present for all notes
6. Mr John Hampson Present for all notes
7. Dr Judith Wardle Present for all notes
8. Prof Matt Stevenson Present for all notes
9. Mr Michael Chambers Present for all notes
10. Dr Nigel Langford Present for all notes
11. Dr Paul Tappenden Present for all notes
12. Dr Peter Selby Present for all notes
13. Dr Richard Nicholas Present for all notes
14. Prof Robert Walton Present for all notes
15. Dr Rebecca Harmston (Committee D) Present for all notes
16. Mr Nigel Westwood (Committee B) Present for all notes

In attendance:

Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes
Frances Sutcliffe Associate Director, National Institute for Health and Care Excellence Present for all notes
Stephanie Callaghan Project Manager, National Institute for Health and Care Excellence Present for all notes
Tanith Musson Administrator, National Institute for Health and Care Excellence Present for all notes
Victoria Kelly Technical Analyst, National Institute for Health and Care Excellence Present for notes 1-17
Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID970], midostaurin for untreated acute myeloid leukaemia [ID894], and tocilizumab for treating giant cell arteritis [1051]

2. The Chair informed the Committee of the non-public observers at this meeting: Lesley Hayes, Gavin Kenny and Edward Murgatroyd

3. Apologies were received from Mr Kamal Balakrishnan, Dr Prithviraj Das, and Prof Andrea Manca

Any other Business

4. None

Appraisal of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID970]
Part 1 – Open session

5. The Chair welcomed the invited experts: Sophie Beale, James Mahon and Yvonne Summers to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Roche to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

7.1. Mr David Chandler, Ms Gail Coster, Mr John Hampson, Dr Rebecca Harmston, Dr Nigel Langford, Prof Andrew Renahan, Dr Peter Selby, Prof Matt Stevenson, Dr Paul Tappenden, Prof Robert Walton, Dr Derek Ward, Dr Judith Wardle and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID970]

7.2. Mr Michael Chambers declared a non-personal specific financial interest as he has received payment from Roche Pharmaceuticals on topics unrelated to this appraisal topic

7.2.1. It was agreed that this declaration would not prevent Mr Michael Chambers from participating in this section of the meeting.

7.3. Dr Richard Nicholas declared a personal non-specific financial interest for his involvement in clinical trials for a different Roche product

7.3.1. It was agreed that this declaration would not prevent Dr Richard Nicholas from participating in this section of the meeting.

8. The Chair asked all NICE Staff to declare any relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID970]

9. The Chair asked all other invited guests to declare their relevant interests.

9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID970]

9.2. Yvonne Summers declared a personal non-specific non-financial interest stating she has participated in Roche advisory boards involved in immune-oncology therapy

9.2.1. It was agreed that this declaration would not prevent Yvonne Summers from participating in this section of the meeting.
10. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. Yvonne Summers excused herself from the meeting and the discussion continued.

13. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

14. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

**Part 2 – Closed session**

15. Discussion on confidential information continued. This information was supplied by the company.

16. The Committee continued to discuss the clinical and cost effectiveness of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID970]

16.1. A vote was taken. The options were:
- Option 1: refer to CDF
- Option 2: do not refer to CDF
The Committee voted for Option 1

17. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Appraisal of midostaurin for untreated acute myeloid leukaemia [ID894]**

**Part 1 – Open session**

18. The Chair welcomed the invited experts: Rob Hodgson, to the meeting and they introduced themselves to the Committee.

19. The Chair welcomed company representatives from Novartis to the meeting.

20. The Chair asked all Committee members to declare any relevant interests

20.1. Mr David Chandler, Mr Michael Chambers, Ms Gail Coster, Mr John Hampson, Dr Rebecca Harmston, Dr Nigel Langford, Dr Richard Nicholas, Prof Andrew Renehan, Dr Peter Selby, Prof Matt Stevenson, Dr Paul Tappenden, Prof Robert Walton, Dr Derek Ward, Dr Judith Wardle and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal
21. The Chair asked all NICE Staff to declare any relevant interests.

21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of midostaurin for untreated acute myeloid leukaemia [ID894]

22. The Chair asked all other invited guests to declare their relevant interests.

22.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of midostaurin for untreated acute myeloid leukaemia [ID894]

23. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

24. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

25. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

26. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

27. Discussion on confidential information continued. This information was supplied by the company.

28. The Committee continued to discuss the clinical and cost effectiveness of midostaurin for untreated acute myeloid leukaemia [ID894]

28.1. The committee decision was based on consensus.

29. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of tocilizumab for treating giant cell arteritis [1051]

Part 1 – Open session
30. The Chair welcomed the invited experts: Kate Gilbert, John Mills, Susan Mollan, Stephen Palmer, Sahar Sharif to the meeting and they introduced themselves to the Committee.

31. The Chair welcomed company representatives from Roche to the meeting.

32. The Chair asked all Committee members to declare any relevant interests

32.1. Mr David Chandler, Ms Gail Coster, Mr John Hampson, Dr Rebecca Harmston, Dr Nigel Langford, Prof Andrew Renehan, Dr Peter Selby, Prof Matt Stevenson, Dr Paul Tappenden, Prof Robert Walton, Dr Derek Ward, Dr Judith Wardle and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID970]

32.2. Mr Michael Chambers declared a non-personal specific financial interest as he has received payment from Roche Pharmaceuticals on topics unrelated to this appraisal topic

34.2.1. It was agreed that this declaration would not prevent Mr Michael Chambers from participating in this section of the meeting.

32.3. Dr Richard Nicholas declared a personal non-specific financial interest for his involvement in clinical trials for a different Roche product

34.3.1. It was agreed that this declaration would not prevent Dr Richard Nicholas from participating in this section of the meeting.

33. The Chair asked all NICE Staff to declare any relevant interests.

33.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID970]

34. The Chair asked all other invited guests to declare their relevant interests.

34.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID970]

34.2. Susan Mollan declared a personal non-specific non-financial interest stating that she had previously participated on advisory boards for Roche

34.2.1. It was agreed that this declaration would not prevent Susan Mollan from participating in this section of the meeting.
35. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

36. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

37. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

38. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

**Part 2 – Closed session**

39. Discussion on confidential information continued. This information was supplied by the company.

40. The Committee continued to discuss the clinical and cost effectiveness of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID970]

40.1. The committee decision was based on consensus

41. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Date, time and venue of the next meeting**

Wednesday 21 February 2018 National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.